Longeveron Announces Pricing of $5.25 Million Public Offering Longeveron prices $5.15 million public offering with certain board member and insider participation.

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.